Maxcyte (MXCT) Operating Expenses (2020 - 2026)

Maxcyte (MXCT) has 7 years of Operating Expenses data on file, last reported at $14.3 million in Q1 2026.

• Quarterly Operating Expenses fell 32.66% year-over-year to $14.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $71.8 million (down 12.14% YoY) and the FY2025 annual result came in at $78.7 million, down 4.86% from the prior year.
• Operating Expenses declined to $14.3 million in Q1 2026 per MXCT's latest filing, from $16.9 million in the prior quarter.
• Across five years, Operating Expenses topped out at $22.2 million in Q1 2024 and bottomed at $14.3 million in Q1 2026.
• The 5-year median for Operating Expenses is $20.3 million (2024), against an average of $19.2 million.
• The widest annual swing landed in 2022, when Operating Expenses surged 60.38%; it then sank 32.66% in 2026.
• Tracing MXCT's Operating Expenses over 5 years: stood at $17.6 million in 2022, then climbed by 25.87% to $22.2 million in 2023, then retreated by 12.96% to $19.3 million in 2024, then decreased by 12.41% to $16.9 million in 2025, then retreated by 15.66% to $14.3 million in 2026.
• Per Business Quant, the three latest MXCT Operating Expenses figures stand at $14.3 million (Q1 2026), $16.9 million (Q4 2025), and $19.4 million (Q3 2025).

Peer Comparison